In fact, lower IRRs were observed during both the initial (012 months) and late (1324 months) exposed periods compared with pretreatment, a pattern also seen for SGLT-2 and DPP-4 inhibitors, possibly reflecting increased healthcare contact or a healthier lifestyle during treatment
[3] For chronic weight management, Wegovy is administered at higher doses, up to 2.4 mg weekly, as an adjunct to reduced-calorie diet and increased physical activity in patients with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related comorbidity
Vo HVT, Patton GN, Park JS, Kim SJ, Kim N, Lee HJ
Regarding non-fatal myocardial infarction, there was no statistically significant difference (RR 1.18
These common effects are generally manageable and do not indicate pancreatitis
This system takes the thinking out of eating, which is exactly what you need when tirzepatide makes food feel like a chore rather than a pleasure